Quince Therapeutics, Inc. announced the appointment of Dr. William Whitehouse to its Scientific Advisory Board (SAB). Dr. Whitehouse is an Honorary Clinical Associate Professor at the University of Nottingham and a recently retired Consultant Paediatric Neurologist, with over 20 years of experience caring for patients with Ataxia-Telangiectasia (A-T).
Dr. Whitehouse joins seven founding members of Quince's SAB, which comprises leading experts across various medical and scientific disciplines. His specific expertise in A-T is expected to provide valuable counsel as the company advances its lead asset, EryDex, for this rare pediatric neurodegenerative disease.
The SAB's role is to provide expert insight and advice for EryDex's development and to support the strategic expansion of Quince's pipeline into other rare disease indications. Dr. Whitehouse expressed his enthusiasm to collaborate and support the advancement of EryDex as a potential first-to-market treatment for the underserved A-T patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.